Spojené štáty - angličtina - NLM (National Library of Medicine)

hyvee inc - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl) - doxylamine succinate 25 mg

Spojené štáty - angličtina - NLM (National Library of Medicine)

rite aid corporation - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl) - doxylamine succinate 25 mg -  nighttime sleep-aid helps to reduce difficulty in falling asleep

Spojené štáty - angličtina - NLM (National Library of Medicine)

costco wholesale corporation - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl) - doxylamine succinate 25 mg - nighttime sleep-aid helps to reduce difficulty in falling asleep

Spojené štáty - angličtina - NLM (National Library of Medicine)

h e b - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl) - doxylamine succinate 25 mg - nighttime sleep-aid helps to reduce difficulty in falling asleep

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sigma company limited - codeine phosphate hemihydrate,doxylamine succinate,paracetamol -

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 10 mg; doxylamine succinate, quantity: 5.1 mg - tablet, uncoated - excipient ingredients: crospovidone; lactose monohydrate; stearic acid; magnesium stearate; maize starch; ethanol; povidone; microcrystalline cellulose - for the temporary relief of acute moderate pain and fever.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; doxylamine succinate, quantity: 5 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: stearic acid; crospovidone; glyceryl monostearate; magnesium stearate; lactose monohydrate; povidone; pregelatinised maize starch - dolased forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Spojené štáty - angličtina - NLM (National Library of Medicine)

granules india limited - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - doxylamine succinate 6.25 mg - pain reliever/fever reducer cough suppressant antihistamine nasal decongestant • temporarily relieves these symptoms due to cold and flu: sneezing itching of the nose, throat or watery eyes due to hay fever cough nasal congestion sinus congestion and pressure sore throat headache minor aches and pains runny nose • helps clear nasal passages and shrinks swollen membranes • temporarily reduces fever • with any other drug containing acetaminophen (prescription or nonprescription). if you are not sure whether a drug contains acetaminophen, ask a doctor or pharmacist. • if you are now taking a prescription monoamine oxidase inhibitor (maoi) (certain drugs for depression, psychiatric, or emotional conditions, or parkinson’s disease), or for 2 weeks after stopping the maoi drug. if you do not know if your prescription drug contains an maoi, ask a doctor or pharmacist before taking this product.

Spojené štáty - angličtina - NLM (National Library of Medicine)

bryant ranch prepack - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use doxylamine succinate and pyridoxine hydrochloride delayed-release tablets have not been studied in women with hyperemesis gravidarum. doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are contraindicated in women with any of the following conditions: - known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation - monoamine oxidase (mao) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride delayed-release tablets [see drug interactions (7.1)] . risk summary doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are intended for the treatment of nausea and vomiting of pregnancy

Spojené štáty - angličtina - NLM (National Library of Medicine)

bionpharma inc., - doxylamine succinate (unii: v9bi9b5yi2) (doxylamine - unii:95qb77jkpl), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z) - doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. limitations of use doxylamine succinate and pyridoxine hydrochloride delayed-release tablets havenot been studied in women with hyperemesis gravidarum. doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are contraindicated in women with any of the following conditions: - known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation. - monoamine oxidase (mao) inhibitors intensify and prolong the adverse central nervous system effects of doxylamine succinate and pyridoxine hydrochloride [see drug interactions (7.1)] . risk summary doxylamine succinate and pyridoxine hydrochloride is intended for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. maternal risks are discussed throughout the labeling. no increased risk for congenital malformations has been reported in epidemiologic studies in pregnant women. in the u.s. general population, the estimated background risks for major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. data human data the combination of doxylamine succinate and pyridoxine hydrochloride has been the subject of many epidemiological studies (cohort, case control and meta-analyses) designed to detect possible teratogenicity. a meta-analysis of 16 cohort and 11 case-control studies published between 1963 and 1991 reported no increased risk for malformations from first trimester exposures to doxylamine succinate and pyridoxine hydrochloride, with or without dicyclomine hydrochloride. a second meta-analysis of 12 cohort and 5 case-control studies published between 1963 and 1985 reported no statistically significant relationships between fetal abnormalities and the first trimester use of the combination doxylamine succinate and pyridoxine hydrochloride with or without dicyclomine hydrochloride. women should not breastfeed while using doxylamine succinate and pyridoxine hydrochloride. the molecular weight of doxylamine succinate is low enough that passage into breast milk can be expected. excitement, irritability and sedation have been reported in nursing infants presumably exposed to doxylamine succinate through breast milk. infants with apnea or other respiratory syndromes may be particularly vulnerable to the sedative effects of doxylamine succinate and pyridoxine hydrochloride resulting in worsening of their apnea or respiratory conditions. pyridoxine hydrochloride is excreted into breast milk. there have been no reports of adverse events in infants presumably exposed to pyridoxine hydrochloride through breast milk. the safety and effectiveness of doxylamine succinate and pyridoxine hydrochloride in children under 18 years of age have not been established. fatalities have been reported from doxylamine overdose in children. the overdose cases have been characterized by coma, grand mal seizures and cardiorespiratory arrest. children appear to be at a high risk for cardiorespiratory arrest. a toxic dose for children of more than 1.8 mg/kg has been reported. a 3-year-old child died 18 hours after ingesting 1,000 mg doxylamine succinate. however, there is no correlation between the amount of doxylamine ingested, the doxylamine plasma level and clinical symptomatology.